Abstract

Basics of Compounding: The "Negative" List

Author(s): Allen Loyd V

Issue: Jul/Aug 2015 - Volume 19, Number 4

Page(s): 311-313

Download in electronic PDF format for $75

Abstract

H.R. 3204 requires the formation of a Pharmacy Compounding Advisory Committee to address the following: The “Negative List”; The “Positive List of Active Pharmaceutical Ingredients”; and “Demonstrable Difficulties in Compounding.” At the first meeting of the Pharmacy Compounding Advisory Committee, the Committee addressed the drug products that have been withdrawn or removed from the market and cannot be compounded because they have been found to be unsafe or not effective. This article provides a current list of drugs that cannot be used in compounding, as well as a “kit” where the combination of ingredients/products cannot be compounded.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Nov/Dec 2016 Pg. 457-458	U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List) Author(s):
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Sep/Oct 2015 Pg. 389-390	Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Author(s): Allen Loyd V Jr
Jul/Aug 2015 Pg. 311-313	Basics of Compounding: The "Negative" List Author(s): Allen Loyd V
Sep/Oct 2021 Pg. 358-362	Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA Author(s): Cabaleiro Joe
Mar/Apr 2018 Pg. 92	PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing Author(s): Allen Loyd V Jr
Mar/Apr 2015 Pg. 104-106	Standing Together Fixing the Drug Quality and Security Act Author(s): Miller David G
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Nov/Dec 2016 Pg. 477-479	The "Lists": What Do They Mean? Author(s): Voliva John
Nov/Dec 2015 Pg. 487-488	U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Author(s): Allen Loyd V Jr
Jan/Feb 2005 Pg. 44-46	The US FDA List of Drugs Not to Be Used in Compounded Medications for Humans (the "Negative List") Author(s): Allen Loyd V Jr, Ashworth Lisa D
Sep/Oct 2014 Pg. 379-380	Final Guidance for Pharmacy Compounding of Human Drug Products Under Section 503A Author(s): Blankenship Cynthia E
Jan/Feb 2015 Pg. 57-58	Basics of Compounding: The Revised "Not to Compound List" Author(s): Allen Loyd V Jr
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
Mar/Apr 2017 Pg. 95-102	U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Author(s): Yoch Doug
Jan/Feb 2014 Pg. 35-36	U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013 Author(s): Miller David G
Jul/Aug 2020 Pg. 296-297	Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Author(s): Brunner Scott
Nov/Dec 2015 Pg. 453-463	Applying Quality of Design Concepts to Pharmacy Compounding Author(s): Timko Robert J
Jul/Aug 2004 Pg. 269-274	Current Topical Treatments in Wound Healing - Part 1 Author(s): Helmke Christopher D